SILVER SPRING, Md., March 21, 2025 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G) to…

HOUSTON, March 21, 2025 /PRNewswire/ — One of the nation’s foremost constitutional law scholars, Erwin Chemerinsky, dean of the University of California, Berkeley School of Law, will be the keynote speaker of the annual Yale L. Rosenberg Lecture at the University of Houston Law Center….

Le NCDPB est une tumeur maligne hématologique agressive dont le pronostic est historiquement mauvais VisualDx est un système de support décisionnel clinique utilisé par plus de 2 300 hôpitaux, cliniques et écoles de médecine dans le monde Le système VisualDx vise à améliorer…

NEW YORK, March 21, 2025 /PRNewswire/ — TO: ALL RECORD HOLDERS AND ALL BENEFICIAL HOLDERS OF AIMMUNE THERAPEUTICS, INC. (“AIMMUNE” OR THE “COMPANY”) COMMON STOCK WHO HELD SUCH STOCK AT ANY TIME DURING THE PENDENCY OF THE TENDER OFFER INVOLVING AIMMUNE, SOCIÉTÉ DES PRODUITS NESTLÉ S.A….

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.